Sanofi (SNY) Stock Forecast & Price Target

$47.67 -0.11 (-0.23%)

(As of 11:58 AM ET)

Sanofi - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 4 Analyst Ratings

Sell
0

Hold
2

Buy
2

Based on 4 Wall Street analysts who have issued ratings for Sanofi in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 4 analysts, 2 have given a hold rating, 1 has given a buy rating, and 1 has given a strong buy rating for SNY.

Consensus Price Target

$57.50
20.62% Upside

According to the 4 analysts' twelve-month price targets for Sanofi, the average price target is $57.50. The highest price target for SNY is $60.00, while the lowest price target for SNY is $55.00. The average price target represents a forecasted upside of 20.62% from the current price of $47.67.

Get the Latest News and Ratings for SNY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Sanofi and its competitors.

SNY Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	2 Buy rating(s)	6 Buy rating(s)
Hold	2 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$57.50	$57.50	$57.50	$60.00
Forecasted Upside	20.62% Upside	7.96% Upside	2.29% Upside	29.14% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Moderate Buy

[625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

SNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Sanofi Stock vs. The Competition

Type	Sanofi	Medical Companies	S&P 500
Consensus Rating Score	2.75	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	20.49% Upside	27,482.23% Upside	9.87% Upside
News Sentiment Rating	Positive News See Recent SNY News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/17/2024	Citigroup 3 of 5 stars	P. Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/26/2024	Argus 2 of 5 stars		Boost Target	Buy ➝ Buy	$55.00 ➝ $60.00	+13.92%
1/23/2024	Morgan Stanley 3 of 5 stars		Initiated Coverage	Equal Weight	$55.00	+8.20%
12/5/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral
10/30/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
9/5/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy
4/28/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Hold ➝ Sell
3/27/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight
12/16/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy ➝ Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:25 PM ET.

Should I Buy Sanofi Stock? SNY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, November 3, 2024. Please send any questions or comments about these Sanofi pros and cons to contact@marketbeat.com.

Sanofi
Bull Case

Here are some ways that investors could benefit from investing in Sanofi:

Sanofi's recent EPS of $0.93 for the quarter exceeded analysts' consensus estimates by $0.05, indicating strong financial performance.
Sanofi's revenue growth of 7.8% year-over-year demonstrates positive momentum in the company's core business operations.
Analysts have raised their price targets for Sanofi, with a consensus rating of "Moderate Buy" and a price target of $57.50, suggesting potential upside.
Sanofi's diverse business segments in Pharmaceuticals, Vaccines, and Consumer Healthcare provide a well-rounded investment opportunity in the healthcare sector.
Sanofi's current stock price of $57.63 offers an entry point for investors to capitalize on potential future growth.

Sanofi
Bear Case

Investors should be bearish about investing in Sanofi for these reasons:

Sanofi's revenue for the quarter fell short of analysts' consensus estimates, signaling potential challenges in meeting market expectations.
Sanofi's PE ratio of 28.96 and price-to-earnings-growth ratio of 1.62 may indicate the stock is currently trading at a premium valuation.
Sanofi's 1-year high of $58.97 suggests limited room for immediate capital appreciation based on historical price levels.
Sanofi's debt-to-equity ratio of 0.17 may raise concerns about the company's leverage and financial stability in the current market environment.
Sanofi's beta of 0.60 indicates lower volatility compared to the market average, potentially limiting short-term trading opportunities for investors seeking higher returns.

SNY Forecast - Frequently Asked Questions

: According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Sanofi is $57.50, with a high forecast of $60.00 and a low forecast of $55.00.
: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last twelve months. There are currently 2 hold ratings, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SNY shares.
: According to analysts, Sanofi's stock has a predicted upside of 20.62% based on their 12-month stock forecasts.
: Over the previous 90 days, Sanofi's stock had 1 upgrade by analysts.
: Sanofi has been rated by research analysts at Citigroup in the past 90 days.
: Analysts like Sanofi less than other "medical" companies. The consensus rating score for Sanofi is 2.75 while the average consensus rating score for "medical" companies is 2.80. Learn more on how SNY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)

Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…

Get Your Free Gold Guide

This page (NASDAQ:SNY) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sanofi (SNY) Stock Forecast & Price Target